Workflow
UroGen Pharma(URGN)
icon
Search documents
UroGen Pharma(URGN) - 2024 Q2 - Quarterly Results
2024-08-13 12:01
Exhibit 99.1 UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights • Potential for an FDA decision as early as the first quarter of 2025, assuming priority review • UGN-102 Phase 3 ENVISION trial demonstrated an unprecedented 82.3% Duration of Response at 12 Months by Kaplan-Meier analysis in LG-IR-NMIBC patients who achieved a complete response at three months • Ended Q2 2024 with $241.3 million in cash, cash equivalents ...
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
ZACKS· 2024-08-02 14:56
Shares of Urogen Pharma (URGN) have gained 5.4% over the past four weeks to close the last trading session at $15.82, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $42.88 indicates a potential upside of 171.1%. The average comprises four short-term price targets ranging from a low of $18 to a high of $60, with a standard deviation of $18.56. While the lowest estimate indicates ...
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
ZACKS· 2024-07-17 14:56
For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 2.2%. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an inv ...
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Newsfilter· 2024-06-17 20:46
TD Cowen and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. is acting as lead manager for the proposed offering. Ladenburg Thalmann is acting as comanager for the proposed offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to re ...
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
ZACKS· 2024-06-17 10:01
Urogen Pharma (URGN) shares soared 9.7% in the last trading session to close at $19.20. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 32.5% gain over the past four weeks. This company is expected to post quarterly loss of $0.88 per share in its upcoming report, which represents a year-over-year change of +14.6%. Revenues are expected to be $23.69 million, up 12% from the year-ago quarter. For Urogen Pharma, the consensus EPS es ...
UroGen Pharma(URGN) - 2024 Q1 - Earnings Call Transcript
2024-05-13 22:30
Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Don Kim - CFO Jeff Bova - Chief Commercial Officer Operator Vincent Perrone During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to JELMYTO, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue opportunities, our commercialization strategy and expectatio ...
UroGen Pharma(URGN) - 2023 Q4 - Earnings Call Transcript
2024-03-15 00:13
Importantly, in patient interviews conducted during the ENVISION trial patients overwhelmingly prefer UGN102 and said they would recommend it to other patients, highlighting the lack of disruption to daily life and that UGN-102 was less invasive, less painful and less time consuming than the standard of care. Finally, as Liz mentioned at the beginning of the call, we are pushing ahead with next-generation formulations of our upper tract and bladder products for low-grade urothelial cancers. We look forward ...
UroGen Pharma(URGN) - 2023 Q4 - Annual Report
2024-03-14 12:17
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter) (Sta ...
UroGen Pharma(URGN) - 2023 Q4 - Annual Results
2024-03-14 12:16
Exhibit 99.1 "In 2023, UroGen achieved important operational and clinical milestones, setting us up for further success in the coming years," said Liz Barrett, President, and Chief Executive Officer of UroGen. "The Phase 3 ATLAS and ENVISION trials both produced meaningful and unprecedented results underscoring the potential of UGN-102 to fundamentally change the way patients with low-grade intermediate-risk non-muscle invasive bladder cancer are treated. We look forward to reporting the 12-month duration o ...
UroGen Pharma(URGN) - 2023 Q3 - Earnings Call Transcript
2023-11-14 19:59
Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Dong Kim - CFO Jeffrey Bova - Chief Commercial Officer Leland Gershell - Oppenheimer Raghuram Selvaraju - H.C. Wainwright & Co. Boris Peaker - TD Cowen Paul Choi - Goldman Sachs Group Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today's conference is being recorded. ...